Septerna, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Septerna reported Q2 2026 net loss of $13.0M (vs. $24.8M in Q2 2025) on $26.7M Novo Nordisk collaboration revenue. Cash, equivalents, and marketable securities totaled $516.5M as of June 30, 2026 (vs. $548.7M Dec 31, 2025), with management guidance that existing cash supports operations at least into 2029. Lead program SEP-479 Phase 1 trial ongoing; observed half-life of 3–4 days supports once-daily dosing, with SAD/MAD data expected Q1 2027.
Why this rating
Routine quarterly results with positive clinical progress and adequate cash runway (141% of market cap), but no material business-changing event; modest burn and continued milestone achievement
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.